概要
Antimicrobial resistance (AMR) is one of the major threats to human health in the 21st century, with some bacterial pathogens acquiring resistance to all clinically available antibiotics. Worldwide, infections caused by multi-drug resistant (MDR) bacteria are now a major cause of morbidity & mortality and have markedly enhanced healthcare costs.
The workshop presents a unique opportunity to hear directly from the regulatory and subject matter experts working on Drug Development of Anti-Infectives.
プログラム委員会
-
Edward M. Cox, MD, MPH Vice President, Regulatory Affairs
Regeneron, United States -
Sumathi Nambiar, MD, MPH Senior Director, Child Health and Innovation Leadership Department
Johnson & Johnson, United States -
Anand Eswaraiah Head, Medical and Regulatory Affairs
Syngene International, India -
Sudheendra Kulkarni Senior Technical Advisor,
FDA, India -
Kristan Callahan International Relations Specialist
U.S. Food and Drug Administration, India -
Anupama Ramkumar Principal Consultant & CEO
Arkus Research, India -
Chandana Pal Accreditation & Quality Systmes Incharge
Apollo Research & Innovations (ARI), India -
Srikanth Tripathy Director in Charge
National Institute for Research in Tuberculosis, India
